U. Klaassen

948 total citations
31 papers, 777 citations indexed

About

U. Klaassen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, U. Klaassen has authored 31 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Pathology and Forensic Medicine. Recurrent topics in U. Klaassen's work include Cancer Treatment and Pharmacology (22 papers), Colorectal Cancer Treatments and Studies (17 papers) and Breast Cancer Treatment Studies (7 papers). U. Klaassen is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Colorectal Cancer Treatments and Studies (17 papers) and Breast Cancer Treatment Studies (7 papers). U. Klaassen collaborates with scholars based in Germany, United States and Switzerland. U. Klaassen's co-authors include S. Seeber, M. Namer, Benjamin Winograd, Jacques Bonneterre, J.-M. Nabholtz, G. Catimel, H. Wilke, Karen A. Gelmon, M. Spielmann and M. Bontenbal and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

U. Klaassen

29 papers receiving 741 citations

Peers

U. Klaassen

ONCOL

PRM

DERMA

B Leone Argentina

Kenichi Harano Japan

F.M. Delgado France

Saverio Danese Italy

Rubina Qamar United States

Jean Pierre Delord France

Peter C. Ungaro United States

S. Vukelja United States

Lucrezia Silvestro Italy

Volker Moebus Germany

B Leone Argentina

U. Klaassen

446 ×0.7

ONCOL

200 ×1.0

133 ×1.0

PRM

105 ×0.9

70 ×0.7

DERMA

Citations per year, relative to U. Klaassen U. Klaassen (= 1×) peers B Leone

Countries citing papers authored by U. Klaassen

Since Specialization

Citations

This map shows the geographic impact of U. Klaassen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Klaassen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Klaassen more than expected).

Fields of papers citing papers by U. Klaassen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Klaassen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Klaassen. The network helps show where U. Klaassen may publish in the future.

Co-authorship network of co-authors of U. Klaassen

This figure shows the co-authorship network connecting the top 25 collaborators of U. Klaassen. A scholar is included among the top collaborators of U. Klaassen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Klaassen. U. Klaassen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kloke, O., U. Klaassen, C. Oberhoff, et al.. (1999). Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Breast Cancer Research and Treatment. 55(1). 51–59. 31 indexed citations

Vanhoefer, U., M. R. Müller, Ralf A. Hilger, et al.. (1999). Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. British Journal of Cancer. 81(8). 1304–1310. 21 indexed citations

Harstrick, A., U. Klaassen, Wilfried Eberhardt, & S. Seeber. (1999). Role of Chemotherapy Against Micrometastatic Cancer. Cancer and Metastasis Reviews. 18(1). 151–172. 1 indexed citations

Klaassen, U., A. Harstrick, Dirk Strumberg, Hans‐Joachim Wilke, & S. Seeber. (1998). Paclitaxel plus ifosfamide in advanced ovarian cancer. Anti-Cancer Drugs. 9(4). 359–362. 5 indexed citations

Klaassen, U., Hans‐Joachim Wilke, A. Harstrick, et al.. (1998). Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: Results of a phase II study. Annals of Oncology. 9(1). 45–50. 13 indexed citations

Klaassen, U., H. Wilke, A. Harstrick, et al.. (1998). Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. Anti-Cancer Drugs. 9(3). 203–208. 14 indexed citations

Bois, Andreas du, Hans‐Joachim Lück, K. Buser, et al.. (1997). Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. European Journal of Cancer. 33(3). 379–384. 19 indexed citations

Strumberg, Dirk, et al.. (1997). Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. Anti-Cancer Drugs. 8(3). 293–295. 6 indexed citations

Klaassen, U., H. Wilke, Carolin Müller, et al.. (1997). Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer.. PubMed. 11(4 Suppl 3). 38–40. 2 indexed citations

10.

Klaassen, U. & S. Seeber. (1997). Metastatic breast cancer: treatment with fluorouracil-based combinations.. PubMed. 11(9 Suppl 10). 69–73. 1 indexed citations

11.

Harstrick, A., Hans‐Joachim Wilke, Wilfried Eberhardt, et al.. (1996). A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer. Oncology Research and Treatment. 19(2). 153–156. 20 indexed citations

12.

Wilke, Hans‐Joachim, U. Klaassen, W. Achterrath, et al.. (1996). Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Annals of Oncology. 7(1). 55–58. 14 indexed citations

13.

Nabholtz, J.-M., Karen A. Gelmon, M. Bontenbal, et al.. (1996). Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.. Journal of Clinical Oncology. 14(6). 1858–1867. 331 indexed citations

14.

Klaassen, U., H. Wilke, Dirk Strumberg, et al.. (1996). Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. European Journal of Cancer. 32(3). 547–549. 60 indexed citations

15.

Klaassen, U., A. Harstrick, H. Wilke, & S. Seeber. (1996). Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.. PubMed. 23(1 Suppl 1). 44–7. 13 indexed citations

16.

Klaassen, U., A. Harstrick, N. Schleucher, et al.. (1996). Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines. British Journal of Cancer. 74(2). 224–228. 19 indexed citations

17.

Klaassen, U., Hans‐Joachim Wilke, Dirk Strumberg, et al.. (1995). 360 Phase I/II study with paclitaxel in combination with weekly high dose 5-FU/Folinic acid in the treatment of metastatic breast cancer. European Journal of Cancer. 31. S78–S78. 6 indexed citations

18.

Weh, H.J., H. Wilke, Judith Dierlamm, et al.. (1994). Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Annals of Oncology. 5(3). 233–237. 65 indexed citations

19.

Klaassen, U., et al.. (1994). Randomized Trial of Two Doses of Taxol in Metastatic Breast Cancer: An Interim Analysis. Oncology Research and Treatment. 17(1). 86–90. 36 indexed citations

20.

Klaassen, U., Carsten Bokemeyer, & H. J. Illiger. (1992). Metastatic Bone Marrow Involvement in Malignant Germ Cell Tumors. Oncology Research and Treatment. 15(5). 394–396.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact